| 產(chǎn)品編號(hào) | bs-0623R-Bio |
| 英文名稱 | Rabbit Anti-Cyclin D1/Biotin Conjugated antibody |
| 中文名稱 | 生物素標(biāo)記的周期素D1抗體 |
| 別 名 | Cyclin D1; CyclinD1; Cyclin-D1; B cell ccl/lymphoma 1; B cell leukemia 1; B-cell CLL/lymphoma 1; B-cell leukemia 1; B-cell lymphoma 1 protein; BCL-1; BCL1; BCL1 oncogene; CCND 1; CCND1; CCND1 protein; CCND1/FSTL3 fusion gene, included; CCND1/IGHG1 fusion gene; CCND1/IGHG1 fusion gene, included; CCND1/IGLC1 fusion gene, included; CCND1/PTH fusion gene, included; Parathyroid adenomatosis 1; PRAD1; FSTL3; CCND1_HUMAN; AI327039; B cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1 oncogene; CCND1/FSTL3 fusion gene, included; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 細(xì)胞周期蛋白 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Rat, (predicted: Mouse, Dog, ) |
| 產(chǎn)品應(yīng)用 | WB=1:50-200 ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 32kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Cyclin D1 N-terminus |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. [provided by RefSeq, Jul 2008]. Function: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma (RB)protein family including RB1 and regulates the cell-cycle duringG(1)/S transition. Phosphorylation of RB1 allows dissociation ofthe transcription factor E2F from the RB/E2F complex and thesubsequent transcription of E2F target genes which are responsiblefor the progression through the G(1) phase. Hypophosphorylates RB1in early G(1) phase. Cyclin D-CDK4 complexes are major integratorsof various mitogenenic and antimitogenic signals. Also substratefor SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent mannerand repressing its transcriptional activity. Component of theternary complex, cyclin D1/CDK4/CDKN1B, required for nucleartranslocation and activity of the cyclin D-CDK4 complex. Subunit: Interacts with FBXO4. Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation and modulationof CDK4-mediated kinase activity. Interacts directly with CDKN1B.Interacts with UHRF2; the interaction ubiquitinates CCND1 andappears to occur independently of phosphorylation. Can form similarcomplexes with either CDKN1A or CDKN2A. Interacts with USP2. Subcellular Location: Nucleus. Cytoplasm. Membrane. Note=CyclinD-CDK4 complexes accumulate at the nuclear membrane and are thentranslocated to the nucleus through interaction with KIP/CIP familymembers. Post-translational modifications: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex. Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF(SKP1-cullin-F-box) protein ligase complex containing FBXO31.SCF-type ubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulingene regions. Activation of CCND1 may be oncogenic by directlyaltering progression through the cell cycle. Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15) withthe parathyroid hormone (PTH) enhancer. Defects in CCND1 are a cause of multiple myeloma (MM)[MIM:254500]. MM is a malignant tumor of plasma cells usuallyarising in the bone marrow and characterized by diffuse involvementof the skeletal system, hyperglobulinemia, Bence-Jones proteinuriaand anemia. Complications of multiple myeloma are bone pain,hypercalcemia, renal failure and spinal cord compression. Theaberrant antibodies that are produced lead to impaired humoralimmunity and patients have a high prevalence of infection.Amyloidosis may develop in some patients. Multiple myeloma is partof a spectrum of diseases ranging from monoclonal gammopathy ofunknown significance (MGUS) to plasma cell leukemia. Note=Achromosomal aberration involving CCND1 is found in multiplemyeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Similarity: Belongs to the cyclin family. Cyclin D subfamily. Database links: Entrez Gene: 595 Human Entrez Gene: 12443 Mouse Omim: 168461 Human SwissProt: P24385 Human SwissProt: P25322 Mouse Unigene: 523852 Human Unigene: 667996 Human Unigene: 273049 Mouse Unigene: 22279 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 細(xì)胞周期素D1蛋白（Cyclin D1）是細(xì)胞周期中的重要調(diào)控因子，它作用于細(xì)胞周期的G1→S期調(diào)控點(diǎn)，為G1期的限速步驟。 細(xì)胞周期蛋白D1-Cyclin D1的過(guò)度表達(dá)使細(xì)胞周期G1期縮短，細(xì)胞生長(zhǎng)對(duì)有絲分裂原和粘附信號(hào)的需求降低，最終引發(fā)腫瘤的發(fā)生。該抗原的氨基酸序列抗原決定簇-結(jié)合位點(diǎn)，我們選在了細(xì)胞質(zhì)的粗面內(nèi)質(zhì)網(wǎng)。越來(lái)越多的研究表明。CyclinD1在正常細(xì)胞周期及腫瘤的調(diào)節(jié)中起著重要作用。周期素D1/Bcl-1屬于細(xì)胞周期調(diào)控蛋白家族成員之一，在細(xì)胞周期從G1進(jìn)入S期中起到重要作用。周期素D1的過(guò)度表達(dá)與癌癥的早發(fā)、腫瘤的進(jìn)展和轉(zhuǎn)移相關(guān)。該抗體可用于細(xì)胞周期方面的研究， |
